Genetic Susceptibility Risk Models in Clinical Decision Making Susan M. Domchek, MD Abramson Cancer Center University of Pennsylvania.

Slides:

Advertisements

Similar presentations

Computer Solutions to Identify and Manage Women at High Risk

Advertisements

What Do We Do? Cancer Genetics Service for Wales.

Hereditary GI Cancer Syndromes: Keys to identify high risk patients

Which of the following increases a women’s risk for Breast Cancer? A.Starting her menses at age 14 or older B.Breastfeeding C.Extremely dense breast tissue.

Is mammacarcinoom onder de veertig jaar morfologisch en genetisch een andere ziekte? Marc van de Vijver, Netherlands Cancer Institute, Amsterdam, NL.

10 November 2011 Genetic counseling for breast cancer risk Aichu Huang, MS. CGC. Department of Medical Genetics National Taiwan University Hospital.

Familial Cancer Risk Assessment: Breast and Ovarian Cancer Genetics and Primary Care.

A few thoughts on cancer and cancer family syndromes Pamela McGrann, MD. Department of Medical Genetics.

Sponsored by Division of Cancer Control and Population Sciences Division of Cancer Epidemiology and Genetics Office of Women’s Health National Cancer Institute,

Hereditary Factors in Breast Cancer

The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.

Hereditary breast and ovarian cancer Who should be screened and How? Symposium on Cancer Waterloo Inn October 31, 2007 Mala Bahl, MD, MSc.

Genetics and Ovarian Cancer Jeanne M. Schilder, M.D. Associate Professor, Gynecologic Oncology Indiana University Medical Center September 19, 2012.

© 2001 Myriad Genetic Laboratories Northern Nevada Genetic Counseling Robbin Palmer Certified Genetic Counselor

Breast Cancer Risk and Risk Assessment Models

Estimating the penetrances of breast and ovarian cancer in the carriers of BRCA1/2 mutations Silvano Presciuttini University of Pisa, Italy.

CANCER GENETIC COUNSELING NORTH DAKOTA CANCER COALITION CANCER CONFERENCE MAY 18, 2011 Marie Schuetzle, MS, CGC Larissa Hansen, MS.

YOLANDA LAWSON M.D., F.A.C.O.G MADEWELL OBGYN ASSOCIATE ATTENDING BAYLOR UNIVERSITY MEDICAL CENTER Women's Health Screening Guidelines.

Type Of Cancer:Location: CarcinomaEpithelial Cells SarcomaConnective Tissue LeukemiaCirculatory / Lymphatic.

PERFORMANCE OF DIFFERENT MODELS PREDICTING THE PRE-TEST PROBABILITY OF CARRYING MUTATIONS IN BRCA1 OR BRCA2 IN 330 ITALIAN FAMILIES Silvano Presciuttini,

BRCA1 and BRCA2 Mutations and Breast Cancer: An Integrated Approach Using Four Epidemiologic Parameters Monica McClain, PhD. Assistant Director, Biometry.

Genetic Testing for Hereditary Cancer Susceptibility

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

BRCA Mutations and Breast Cancer Ruth Phillips and Patty Ashby.

Genetic and Molecular Epidemiology

The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.

Genetics and Ovarian Cancer June 16, 2015 Ovarian Cancer Alliance of Oregon and SW Washington Becky Clark, MS, CGC Genetic Counselor.

Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA

Corrine Fillman, M.S., C.G.C. Connective Tissue Gene Tests (CTGT) 6580 Snowdrift Road, Suite 300 Allentown, PA

The Benefits and Challenges of Genetic Counseling: A Surgical Oncologist Perspective Hank C. Hill, MD Surgical Oncologist St. Vincent’s Surgical Associates.

Jo Anne Zujewski, MD Center for Global Health National Cancer Institute, U.S.A. Dar es Salaam September 11, 2014 Breast Cancer Risk Factors and Prevention.

Breast Cancer Genetic Risk Communicating with Your Family Mary B. Daly, M.D., Ph.D. April 3, 2012.

Dr Matt Hewitt Prophylactic Bilateral Salpingoophorectomy.

Cancer Risk Assessment Judith A Westman MD Clinical Director Division of Human Genetics.

Criteria for Assessment of Performance of Cancer Risk Prediction Models: Overview Ruth Pfeiffer Cancer Risk Prediction Workshop, May 21, 2004 Division.

Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.

Ovarian Cancer Risk Reduction Taking oral contraceptives for 5 years can reduce your risk of ovarian cancer by up to 50% Hankinson SE, Colditz GA, Hunter.

Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.

In The Name of God BREAST IMAGING N. Ahmadinejad Medical Imaging Center TUMS.

Gynecological Malignancies. Gynecologic malignancies account for 15% of all cancers in women. Gynecologic malignancies account for 15% of all cancers.

Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.

BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.

Introduction Hereditary predisposition (mutations in BRCA1 and BRCA2 genes) contribute to familial breast cancers. Eighty percent of the.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

Pancreatic Cancer In 2012 there were 43,920 cases of pancreatic cancer. 10% of these cases have a family clustering of pancreatic cancers and associated.

Breast Cancer Surveillance Consortium (BCSC): A Research Infrastructure sponsored by the National Cancer Institute Breast Cancer Risk Models William Barlow,

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

Breast Cancer Ten percent of breast cancer is hereditary. Or 23,000 women a year with a genetic basis for their cancer. The most common mutations in this.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

What Percentage of Cancer is Considered to be Hereditary?

Genetic Counseling Yahwardiah Siregar Sry Suryani W Mutiara Indah Sari.

Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.

The Elliott Breast Center * Baton Rouge, LA *

Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.

Research Brief: Genetic Testing for Hereditary Cancers Craig Morse BIO 101 SNHU.

Hereditary Cancer Predisposition: Updates in Genetic Testing

Pathways involved in hereditary breast cancer

Kyle Salsbery Genetic Counselor

Susan Domchek, MD University of Pennsylvania

Demystifying Cancer Genetics

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Hereditary Gastrointestinal Cancers

Family Tree Presentation

Breast Health Katherine B. Lee, MD, FACP April 26, 2018.

Who in the room would offer BRCA1/2 testing to this patient Who in the room would offer BRCA1/2 testing to this patient? How might the medical management.

Genetic Counseling & Testing for Cancer Risk

The decision tree with the two alternatives.

Specific Tumor Suppressor Genes

HBOC Genetic counseling: major concerns and communication skills

Presentation transcript:

Genetic Susceptibility Risk Models in Clinical Decision Making Susan M. Domchek, MD Abramson Cancer Center University of Pennsylvania

Cancer Risk Evaluation Program Genetic Testing PCP Self-referral Oncologist Models Gail and Claus Screening studies Chemoprevention BSO Screening studies Prevention studies PM >10% <10% +- >25%

BRCA prediction models Logistic regression models (Couch, Shattuck-Eidens, Frank) Bayesian formulations (BRCAPRO) Empiric tables (Frank 2002) Prevalence tables Unique attributes to each model Consideration of testing for women with a probability of 10%

Limitations of family history Adoption Small family size, especially women –Prevalence tables can be very helpful Early deaths Accuracy of cancer information –Stomach cancer in women –Obtain medical records whenever possible

Limitations of all models Race/ethnicity data How to handle DCIS LCIS “Other” cancers – pancreatic cancer, melanoma, early prostate

Myriad Tables: 21.2% (47% in 2 <50) Couch: 7.7% for family BRCAPro: Dependent on proband – 55% vs 1.6% Variability in models

What is the goal of prior probability models? Identify candidates for testing for BRCA1/BRCA2 –Do we care more about sensitivity or specificity? –Clinically: sensitivity –Economically: specificity Stratify risk of hereditary syndromes –In tested negative families should we do counseling based on PP models?

5/11/ BR_CA 48 2 Skin_CA BR_CA 28 OV_CA d d Eye_Melan Panc_CA 55 d BR_CA 52 d Liver_CA Panc_CA d d d d. 45 “False” negative: what to counsel?

4/26/2004 Which syndrome? What ovarian cancer risk?

Can pathologic features help? BRCA1 mutation related breast cancers –90% are estrogen receptor negative –High grade, aneuploid, “pushing margins” –3% are HER2/neu positive BRCA2 mutation related breast cancers –More like sporadic tumors –Approximately 50% are ER positve –Only 3% HER2/neu positive

Probability of BRCA1 mutation by age, ER status and grade AgeAll (%)Grade 1(%)Grade 2 (%)Grade 3 (%) < ER positive tumors Lahkini et al, JCO 2002

Probability of BRCA1 mutation by age, ER status and grade AgeAll (%) Grade 1(%) Grade 2 (%) Grade 3 (%) < ER positive tumors

Claus and Gail in Hereditary Families

Issues in clinical decision making “Hereditary” patterns that test negative How to define them? Is breast cancer risk assessment accurate? What is their ovarian cancer risk? Risk assessment in VUS?